Project Grant R44AG060878

This R01 Project Grant, awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), provides $6,467,513 to continue funding for the Ante-Amyloid Treatment of Alzheimer's Disease (A3) Trial and the Alzheimer Plasma Extension (APEX) Study. The A3 Trial is testing a low dose of the amyloid-removing monoclonal antibody lecanemab in individuals at the intermediate amyloid stage of Alzheimer's disease, prior to elevated brain amyloidosis. The APEX Study will follow 1,000 participants...

The National Institute on Aging (NIA) awarded a $3,281,385 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the University of California, San Diego (UCSD) to leverage 30 years of Alzheimer's disease clinical trials data. The goal is to examine the role of specific patient phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions. The project will analyze data from 14,602 participants across multiple...

This $499,778 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to S-3 Research LLC aims to co-design a mobile tool to improve diversity and inclusion in Alzheimer's Disease and Related Dementias (ADRD) clinical trial participation. Key objectives include developing an ADRD-specific clinical trial matching algorithm, conducting interviews with older adults and ADRD caregivers to identify participation challenges, and facilitating co-design sessions to create...

This Project Grant award of $366,648 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by New York University to develop statistical methods for enhancing the estimation and modeling of Alzheimer's disease (AD) progression using data from longitudinal cohort studies. The key objectives are to: 1) Enable the use of clinically relevant time origins through proper adjustment for complex truncation and censoring in these studies, to improve clinical trial design...

The National Institute on Aging (NIA), under the Aging Research grant program (CFDA 93.866), has awarded a $4,722,722 Project Grant to Yale University to conduct a pioneering, randomized, double-blind study investigating the potential of anti-TNF therapy (adalimumab) to slow or prevent the emergence of motor and cognitive symptoms in subjects with prodromal synucleinopathies. The study, titled "Immunologic and Imaging Studies with TNF Therapy in Prodromal Synucleinopathies," will...

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $252,124 to Alphamemory, LLC to conduct research targeting the substrate of gamma-secretase for selective amyloid reduction in Alzheimer's disease. The key products or services to be delivered include: Structure-activity relationship (SAR) studies and lead optimization of a compound (C1) to improve drug activity and in vitro ADME properties (Aim 1). In vivo...

This Project Grant award of $353,391.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to validate the use of a "Personal Learning Curve" paradigm as a sensitive marker of early memory decline related to Alzheimer's disease (AD) biomarkers in a large, diverse sample of older adults. The study seeks to determine if this digital cognitive assessment tool, which measures learning over repeated evaluations, can detect subtle AD-related memory failures...

The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Oligomerix Inc. a $499,879 project grant on Aug 20, 2025 to conduct a 13-week oral gavage toxicity study of their drug candidate OLX-07010 in beagle dogs, followed by a 4-week recovery period. This study is intended to de-risk a planned 39-week toxicology study required by the FDA to support the continued clinical development of OLX-07010 for the treatment of Alzheimer's disease (AD)...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $398,046 to the Palo Alto Veterans Institute for Research (PAVIR) to systematically test the combined effects of anti-amyloid treatment and brain stimulation for treating mild cognitive impairment (MCI) and Alzheimer's disease (AD) in a mouse model. The research aims to assess the biochemical response, memory improvements, and electrocorticography (ECoG) changes resulting from the combined...

This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $322,000.00 to Case Western Reserve University to perform the following: Analyze electroencephalographic (EEG) and plasma Alzheimer's disease (AD) biomarker data collected during a previous clinical trial studying the effects of the drug memantine on adolescents and young adults with Down syndrome. The analysis will examine the...